The New Topicals: JAK Inhibitors and Tapinarof
For half a century, treating an inflamed patch of skin meant one of two things: a corticosteroid or, later, a calcineurin inhibitor. Both worked; both had ceilings — steroids thin the skin, calcineurin inhibitors sting. Then, from 2022 onward, a wave of genuinely new molecules arrived that share a single ambition: to switch off inflammation precisely, at a named signalling node, without a single steroid molecule. A cream that blocks the same JAK enzymes as the pills that revolutionised rheumatology. A cream that talks to a receptor better known for sensing dioxin. This is topical immunomodulation growing up — and it is quietly rewriting what a tube of ointment can do.
A 24-year-old man has had white patches spreading across his hands and face for three years — non-segmental vitiligo. He has tried potent steroids and a calcineurin inhibitor with almost nothing to show for it, and he has stopped looking people in the eye. His dermatologist offers something that did not exist when his patches first appeared: a cream, applied twice a day, that blocks an enzyme called JAK. Nothing happens for weeks. Then, at around the third month, faint freckles of colour appear inside the white — islands of pigment creeping back from the hair follicles. By a year, his face is mostly repigmented. For the first time in dermatology, a topical drug has not merely calmed inflammation but reversed a disease of lost pigment. The same molecular idea, in a different cream, is at that moment clearing another patient's psoriasis two floors up.
Why the steroid duopoly needed breaking
The old topicals were blunt instruments dressed up as precision tools. A topical corticosteroid suppresses inflammation by acting on a huge sweep of genes at once — powerful, cheap, and, with prolonged use, guilty of thinning the skin (atrophy), stretch marks, and telangiectasia, especially on the face and folds. The calcineurin inhibitors — tacrolimus and pimecrolimus, covered in the Calcineurin and PDE4 chapter — were the first real steroid-sparing answer: they block the calcineurin–NFAT switch that turns on T-cell cytokines, and they cause no atrophy, which is exactly why they earned their place on the eyelids and face. But they burn on application and carry a much-debated boxed warning, and neither they nor steroids were ever designed against a specific cytokine. The new topicals are: they name the molecular node they hit, and hit little else.
Topical JAK inhibition: ruxolitinib cream
Most of the cytokines that drive skin inflammation — interleukin-4 and interleukin-13 in atopic dermatitis (eczema), interferon-γ in vitiligo — do not act through a receptor with its own built-in enzyme. Instead, their receptors borrow a family of enzymes parked on the inside of the cell membrane: the Janus kinases, JAK1, JAK2, JAK3 and TYK2. When a cytokine binds, the paired JAKs switch on, phosphorylate a transcription factor called STAT, and the STAT walks into the nucleus and turns on the inflammatory programme. This whole relay is the JAK-STAT pathway taught in the Principles of Inflammation section — it is the single wire down which dozens of different cytokines send their message. Ruxolitinib cream blocks JAK1 and JAK2. Cut that wire and the cell simply stops hearing IL-4, IL-13 and interferon-γ, no matter how much of them is present outside.
Picture a busy office switchboard. Dozens of outside callers — IL-4, IL-13, interferon-γ — each dial in on their own line, but every call is put through by the same handful of operators sitting at the board: the JAK enzymes. A corticosteroid is like storming the whole building and pulling every plug. A JAK inhibitor is subtler: it walks up to the switchboard and taps the operators on the shoulder. The callers keep dialling, but no one connects the calls, so the message never reaches the manager's office — the nucleus. Ruxolitinib benches two of those operators, JAK1 and JAK2, and the inflammatory calls simply go unanswered.
Two approvals, one of them a genuine first. Ruxolitinib cream is approved for mild-to-moderate atopic dermatitis, where blocking IL-4/IL-13 signalling calms the itch–scratch cycle quickly. Its second indication is the landmark one: non-segmental vitiligo, where it is the first drug of any kind approved to repigment skin. In vitiligo, interferon-γ signalling (through JAK) drives the CD8 T cells that destroy melanocytes; block that signal and you both call off the attack and let surviving melanocytes — chiefly those hiding in the hair follicle — migrate back out and re-colour the patch. This connects directly to the Hair and Pigment chapter, where the very same JAK logic explains why oral JAK inhibitors regrow hair in alopecia areata: another interferon-driven autoimmune assault, this time on the follicle rather than the melanocyte.
The boxed warning on ruxolitinib cream is inherited, not earned. It is the same class warning carried by the oral JAK inhibitors — serious infections, thrombosis, major cardiovascular events, malignancy — extrapolated from high-dose systemic rheumatology trials in older patients. But a cream is not a pill. Applied to a limited body-surface area, systemic absorption of topical ruxolitinib is very low, and blood levels sit far below those that suppress the marrow or the immune system as a whole. Understanding that gap — a real class signal, applied cautiously to a formulation that barely reaches the bloodstream — is the difference between using the drug rationally and being frightened off it.
- The JAK-STAT pathway is the shared relay dozens of cytokines use; JAK enzymes sit on the receptor's inner face.
- Ruxolitinib cream blocks JAK1/JAK2, deafening the cell to IL-4, IL-13 and interferon-γ.
- Approved for atopic dermatitis and — a first — for non-segmental vitiligo, the first topical repigmenter.
- Repigmentation is slow (months) and follicle-driven — pigment creeps back from the hair units.
- It carries the oral-JAK class boxed warning, but topical systemic absorption and blood levels are very low.
Tapinarof: talking to the aryl hydrocarbon receptor
The strangest target in dermatology turned out to be a friend. Tapinarof is first-in-class: a topical aryl hydrocarbon receptor (AhR) agonist. The AhR is an ancient sensor inside skin cells, evolved to detect environmental molecules — famously dioxin, but also microbial and dietary compounds — and adjust the cell's behaviour accordingly. Tapinarof deliberately switches this receptor on, and the downstream effect is threefold and elegant. First, activated AhR downregulates the Th17 cytokines — chiefly IL-17 — that drive plaque psoriasis, tying it straight into the IL-17/Th17 axis you meet in the Psoriasis chapter. Second, it upregulates the skin-barrier genes (filaggrin, loricrin, involucrin) that a psoriatic or eczematous barrier is starved of, so it is not only anti-inflammatory but barrier-restoring. Third, it exerts an antioxidant effect through the Nrf2 system, mopping up the oxidative stress that keeps inflamed skin inflamed.
Tapinarof is approved for plaque psoriasis and, more recently, for atopic dermatitis — the same dual footprint as ruxolitinib, reached from the opposite molecular direction. Two features make it clinically distinctive. The first is a genuinely unusual benefit: a durable remittive effect. In trials, a meaningful fraction of patients who cleared and then stopped the drug stayed clear for months before any relapse — a "remittive" behaviour almost unheard of for a topical, which usually works only while you keep applying it. The second is its signature side effect: folliculitis, small inflamed spots around hair follicles, a direct and predictable consequence of an agonist acting on follicular AhR. It is usually mild, but it is the finding that flags tapinarof on an exam and at the bedside. Contact dermatitis and headache round out the profile.
Ruxolitinib cream (Opzelura) — JAK1/JAK2 inhibitor, for atopic dermatitis and non-segmental vitiligo (first topical repigmenter). Tapinarof (Vtama) — AhR agonist, for plaque psoriasis and atopic dermatitis; watch for folliculitis and prize its off-drug remission. Roflumilast (Zoryve foam/cream) — a topical PDE4 inhibitor, sibling of the oral crisaborole/apremilast family covered in the PDE4 chapter; it raises intracellular cyclic AMP to damp inflammatory cytokines, is approved for psoriasis (including scalp and intertriginous sites) and seborrhoeic dermatitis, and is prized for being non-greasy and free of the stinging that limits calcineurin inhibitors. Together these three are the front line of steroid-free topical immunomodulation.
The bigger shift: targeted, steroid-free topicals
Step back and a pattern emerges. Each of these agents lands on a single, named node of the inflammatory machine — the JAK-STAT switchboard, the AhR sensor, the PDE4 enzyme — and each spares the skin the atrophy that comes with broad steroid suppression. This is the topical echo of the biologic revolution that reshaped systemic dermatology in the Biologics chapter, brought down to a tube you rub on. The clinical payoff is precise: a face or an eyelid that cannot tolerate months of steroid, an intertriginous fold where atrophy is disastrous, a chronic disease that needs indefinite maintenance without a cumulative steroid burden. The lineage runs straight from the calcineurin inhibitors and topical PDE4 of the previous chapter — the first steroid-sparing generation — to these named-target creams, which finish the sentence the calcineurin inhibitors began: control the inflammation, spare the skin, and, in the case of vitiligo, do something no steroid ever could — bring the colour back.
- Tapinarof is a first-in-class AhR agonist for plaque psoriasis (and atopic dermatitis).
- AhR activation downregulates Th17/IL-17, upregulates barrier genes, and is antioxidant (Nrf2).
- Its standout: durable off-drug remission — rare for any topical.
- Its signature adverse effect is folliculitis, a direct consequence of follicular AhR agonism.
- Roflumilast (topical PDE4) is the third steroid-free option — non-greasy, non-stinging, good on scalp and folds.
- All three spare the skin from steroid atrophy by hitting one named signalling node.
- Treating ruxolitinib cream's boxed warning as if it were a systemic-dose risk. It is an extrapolated class warning; topical absorption and blood levels are very low.
- Expecting fast repigmentation in vitiligo. Colour returns over months from the follicles — abandoning the cream at week six wastes a working drug.
- Mistaking tapinarof-induced folliculitis for a spreading infection or treatment failure — it is an expected, usually mild AhR effect, not a reason to stop reflexively.
A 30-year-old with limited plaque psoriasis on the face and body folds is started on tapinarof cream. Which counselling point is most specifically tied to this drug's mechanism?
- The 2022+ steroid-free topicals each hit one named node — sparing the skin the atrophy of broad steroid suppression.
- Ruxolitinib cream blocks JAK1/JAK2 on the JAK-STAT pathway (silencing IL-4/IL-13 and interferon-γ) — for atopic dermatitis and, uniquely, non-segmental vitiligo, the first topical repigmenter; it carries the oral-JAK class boxed warning despite very low topical absorption.
- Tapinarof is a first-in-class AhR agonist for plaque psoriasis and atopic dermatitis — downregulating Th17/IL-17, restoring barrier genes, antioxidant — famed for off-drug remission and folliculitis as its signature effect.
- Roflumilast (topical PDE4) rounds out the trio; together they extend the steroid-sparing lineage of calcineurin inhibitors toward precise, targeted topical immunomodulation.
- Rook's Textbook of Dermatology — Topical therapy: novel non-steroidal anti-inflammatory agents.
- Wolverton SE. Comprehensive Dermatologic Drug Therapy — Topical JAK inhibitors and aryl hydrocarbon receptor agonists.
- Rosmarin D, et al. Ruxolitinib cream for nonsegmental vitiligo (TRuE-V phase 3 trials). New England Journal of Medicine.
- Lebwohl MG, et al. Tapinarof cream for plaque psoriasis (PSOARING phase 3 trials). New England Journal of Medicine.
- British National Formulary (BNF) — Ruxolitinib, tapinarof and roflumilast (topical) monographs.
- American Academy of Dermatology (AAD) guidelines of care for the topical management of atopic dermatitis and psoriasis.
